Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.